The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Immune checkpoints and their inhibition in cancer and infectious diseases
Open accessAbstract
The development of chronic infections and cancer is facilitated by a variety of immune subversion mechanisms, such as the production of anti‐inflammatory cytokines, induction of regulatory T (Treg) cells, and expression of immune checkpoint molecules, including CTLA‐4 and PD‐1. CTLA‐4, expressed on T cells, interacts with CD80/CD86, thereby limiting T‐cell activation and leading to anergy. PD‐1 is predominantly expressed on T cells and its interaction with PD‐L1 and PD‐L2 expressed on antigen‐presenting cells (APCs) and tumors sends a negative signal to T cells, which can lead to T‐cell exhaustion. Given their role in suppressing effector T‐cell responses, immune checkpoints are being targeted for the treatment of cancer. Indeed, antibodies binding to CTLA‐4, PD‐1, or PD‐L1 have shown remarkable efficacy, especially in combination therapies, for a number of cancers and have been licensed for the treatment of melanoma, nonsmall cell lung cancer, and renal and bladder cancers. Moreover, immune checkpoint inhibitors have been shown to enhance ex vivo effector T‐cell responses from patients with chronic viral, bacterial, or parasitic infection, including HIV, tuberculosis, and malaria. Although the data from clinical trials in infectious diseases are still sparse, these inhibitors have great potential for treating chronic infections, especially when combined with therapeutic vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedImproved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
Dieu-Nosjean, M.-C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, E., de Chaisemartin, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0284 · Cited by 1,031
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Cytotoxic T-Cell Immunity to Influenza
McMichael, A. J., Gotch, F. M., Noble, G. R., & Beare, P. A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198307073090103 · Cited by 927
T-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 875
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Regulatory T cells: friend or foe in immunity to infection?
Mills, K. H. G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1485 · Cited by 702
Self-citationZhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551
Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0620-6 · Cited by 522
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J. L., Brosnahan, K., Imam, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2232 · Cited by 517
Giraldo, N. A., Becht, E., Pagès, F., Skliris, G., Verkarre, V., Vano, Y., Mejean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 507
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
Butler, N. S., Moebius, J., Pewe, L. L., Traore, B., Doumbo, O. K., Tygrett, L. T., Waldschmidt, T. J., Crompton, P. D., & Harty, J. T. (2012) · Nature Immunology · doi:10.1038/ni.2180 · Cited by 482
Targeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 469
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Jarnicki, A. G., Lysaght, J., Todryk, S., & Mills, K. H. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.896 · Cited by 445
Self-citationLiu, S., Lachapelle, J., Leung, S., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 436
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Wang, L., Pino-Lagos, K., de Vries, V. C., Guleria, I., Sayegh, M. H., & Noelle, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710441105 · Cited by 389
Sakai, S., Kauffman, K. D., Sallin, M. A., Sharpe, A. H., Young, H. A., Ganusov, V. V., & Barber, D. L. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005667 · Cited by 347
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis
Lázár-Molnár, E., Chen, B., Sweeney, K. A., Wang, E. J., Liu, W., Lin, J., Porcelli, S. A., Almo, S. C., Nathenson, S. G., & Jacobs, W. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007394107 · Cited by 338
γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Daley, D., Zambirinis, C. P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V. R. K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.046 · Cited by 329
Chew, G. M., Fujita, T., Webb, G. M., Burwitz, B. J., Wu, H. L., Reed, J. S., Hammond, K. B., Clayton, K. L., Ishii, N., Abdel-Mohsen, M., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005349 · Cited by 323
PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Shi, L., Chen, L., Wu, C., Zhu, Y., Xu, B., Zheng, X., Sun, M., Wen, W., Dai, X., Yang, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1352 · Cited by 312
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
Riley, J. L., Mao, M., Kobayashi, S., Biery, M., Burchard, J., Cavet, G., Gregson, B. P., June, C. H., & Linsley, P. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162359999 · Cited by 307
Zhang, J.-Y., Zhang, Z., Wang, X., Fu, J.-L., Yao, J., Jiao, Y., Chen, L., Zhang, H., Wei, J., Jin, L., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044826 · Cited by 302
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Magistrelli, G., Jeannin, P., Herbault, N., Benoit de Coignac, A., Gauchat, J.-F., Bonnefoy, J.-Y., & Delneste, Y. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3596::aid-immu3596>3.0.co;2-y · Cited by 276
Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVR
Stanietsky, N., Rovis, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J., Jonjic, S., & Mandelboim, O. (2013) · European Journal of Immunology · doi:10.1002/eji.201243072 · Cited by 263
Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910341107 · Cited by 256
Miyashita, M., Sasano, H., Tamaki, K., Hirakawa, H., Takahashi, Y., Nakagawa, S., Watanabe, G., Tada, H., Suzuki, A., Ohuchi, N., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0632-x · Cited by 253
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252
Li, J., Jie, H.-B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., Kane, L. P., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 246
Zhang, Y., Huang, S., Gong, D., Qin, Y., & Shen, Q. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.28 · Cited by 241
Diederichsen, A. C. P., v. B. Hjelmborg, J., Christensen, P. B., Zeuthen, J., & Fenger, C. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0388-5 · Cited by 237
Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K. R., Chang, K.-M., Sulkowski, M., Marro, S. O., Anderson, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063818 · Cited by 231
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Baptista, M. Z., Sarian, L. O., Derchain, S. F. M., Pinto, G. A., & Vassallo, J. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.006 · Cited by 230
Targeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients
Peng, G., Li, S., Wu, W., Tan, X., Chen, Y., & Chen, Z. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.07.038 · Cited by 222
Ha, S.-J., Mueller, S. N., Wherry, E. J., Barber, D. L., Aubert, R. D., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071949 · Cited by 211
Bonertz, A., Weitz, J., Pietsch, D.-H. K., Rahbari, N. N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39608 · Cited by 200
Jung, H. I., Jeong, D., Ji, S., Ahn, T. S., Bae, S. H., Chin, S., Chung, J. C., Kim, H. C., Lee, M. S., & Baek, M.-J. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.066 · Cited by 198
Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion
Bucks, C. M., Norton, J. A., Boesteanu, A. C., Mueller, Y. M., & Katsikis, P. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800997 · Cited by 187
Das, S., Suarez, G., Beswick, E. J., Sierra, J. C., Graham, D. Y., & Reyes, V. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3000 · Cited by 184
Fuller, M. J., Callendret, B., Zhu, B., Freeman, G. J., Hasselschwert, D. L., Satterfield, W., Sharpe, A. H., Dustin, L. B., Rice, C. M., Grakoui, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312772110 · Cited by 173
Piras, F., Colombari, R., Minerba, L., Murtas, D., Floris, C., Maxia, C., Corbu, A., Perra, M. T., & Sirigu, P. (2005) · Cancer · doi:10.1002/cncr.21283 · Cited by 168
Differential expression of CTLA-4 among T cell subsets
JAGO, C. B., YATES, J., OLSEN SARAIVA CÂMARA, N., LECHLER, R. I., & LOMBARDI, G. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02478.x · Cited by 167
Finlay, C. M., Walsh, K. P., & Mills, K. H. G. (2014) · Immunological Reviews · doi:10.1111/imr.12164 · Cited by 165
Self-citationBhadra, R., Gigley, J. P., Weiss, L. M., & Khan, I. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015298108 · Cited by 163
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
Wu, W., Shi, Y., Li, S., Zhang, Y., Liu, Y., Wu, Y., & Chen, Z. (2012) · European Journal of Immunology · doi:10.1002/eji.201141852 · Cited by 158
Joshi, T., Rodriguez, S., Perovic, V., Cockburn, I. A., & Stäger, S. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000431 · Cited by 158
Consensus nomenclature for CD8+T cell phenotypes in cancer
Apétoh, L., Smyth, M. J., Drake, C. G., Abastado, J., Apte, R. N., Ayyoub, M., Blay, J., Bonneville, M., Butterfield, L. H., Caignard, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998538 · Cited by 156
Massi, D., Brusa, D., Merelli, B., Ciano, M., Audrito, V., Serra, S., Buonincontri, R., Baroni, G., Nassini, R., Minocci, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu452 · Cited by 151
Ali, O. A., Lewin, S. A., Dranoff, G., & Mooney, D. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0126 · Cited by 151
Evans, A., Riva, A., Cooksley, H., Phillips, S., Puranik, S., Nathwani, A. C., Brett, S. J., Chokshi, S., & Naoumov, N. V. (2008) · Hepatology · doi:10.1002/hep.22419 · Cited by 150
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 146
Self-citationRutigliano, J. A., Sharma, S., Morris, M. Y., Oguin, T. H., McClaren, J. L., Doherty, P. C., & Thomas, P. G. (2013) · Journal of Virology · doi:10.1128/jvi.02851-13 · Cited by 138
Jarnicki, A., Conroy, H., Brereton, C. F., Donnelly, G., Toomey, D., Walsh, K., Sweeney, C. M., Leavy, O., Fletcher, J. M., Lavelle, E. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3797 · Cited by 137
Self-citationThe soluble isoform of CTLA‐4 as a regulator of T‐cell responses
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S., Kaewarpai, T., Xu, H., Vickers, M. A., & Barker, R. N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242529 · Cited by 135
Salvi, S., Fontana, V., Boccardo, S., Merlo, D. F., Margallo, E., Laurent, S., Morabito, A., Rijavec, E., Dal Bello, M. G., Mora, M., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1211-y · Cited by 133
Blockade of CTLA-4 Enhances Host Resistance to the Intracellular Pathogen, Leishmania donovani
Murphy, M. L., Cotterell, S. E. J., Gorak, P. M. A., Engwerda, C. R., & Kaye, P. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4153 · Cited by 133
Hafalla, J. C. R., Claser, C., Couper, K. N., Grau, G. E., Rénia, L., de Souza, J. B., & Riley, E. M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002504 · Cited by 127
Alvarez, I. B., Pasquinelli, V., Jurado, J. O., Abbate, E. H., Musella, R. M., de la Barrera, S., & García, V. (2010) · The Journal of Infectious Diseases · doi:10.1086/654932 · Cited by 126
Shen, L., Gao, Y., Liu, Y., Zhang, B., Liu, Q., Wu, J., Fan, L., Ou, Q., Zhang, W., & Shao, L. (2016) · Scientific Reports · doi:10.1038/srep38362 · Cited by 124
PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M. R., & Goodier, M. R. (2012) · Viral Immunology · doi:10.1089/vim.2011.0096 · Cited by 117
Zhang, Y., Kang, S., Shen, J., He, J., Jiang, L., Wang, W., Guo, Z., Peng, G., Chen, G., He, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000000515 · Cited by 116
Pauken, K. E., & Wherry, E. J. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.016 · Cited by 111
Beswick, E. J., Pinchuk, I. V., Das, S., Powell, D. W., & Reyes, V. E. (2007) · Infection and Immunity · doi:10.1128/iai.00553-07 · Cited by 110
Iraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Araya, R. E., Ziblat, A., Domaica, C. I., Sierra, J. M., Núñez, S. Y., Secchiari, F., Gajewski, T. F., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502291 · Cited by 107
Moore, A., Gallimore, A., Draper, S., Watkins, K., Gilbert, S., & Hill, A. (2005) · Journal of Immunology · doi:10.4049/jimmunol.175.11.7264 · Cited by 105
TGF-β Mediates CTLA-4 Suppression of Cellular Immunity in Murine Kalaazar
Gomes, N. A., Gattass, C. R., Barreto‐de‐Souza, V., Wilson, M. E., & DosReis, G. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2001 · Cited by 104
Karunarathne, D. S., Horne‐Debets, J. M., Huang, J. X., Faleiro, R. J., Leow, C. Y., Amante, F. H., Watkins, T. S., Miles, J. J., Dwyer, P., Stacey, K. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.017 · Cited by 104
Hernández-Ruiz, J., Salaiza‐Suazo, N., Carrada-Figueroa, G., Escoto, S., Ruiz‐Remigio, A., Rosenstein, Y., Zentella‐Dehesa, A., & Becker, I. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000871 · Cited by 102
Woods, D. M., Woan, K. V., Cheng, F., Wang, H., Perez-Villarroel, P., Lee, C., Lienlaf, M., Atadja, P. W., Seto, E., Weber, J. S., et al. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e328364c0ed · Cited by 101
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
Leite, K. R. M., Reis, S. T., Junior, J. P., Zerati, M., Gomes, D. D. O., Camara-Lopes, L. H. A., & Srougi, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0414-x · Cited by 98
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Mao, H., Zhang, L., Yang, Y., Zuo, W., Bi, Y., Gao, W., Deng, B., Sun, J., Shao, Q., & Qu, X. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793605811 · Cited by 97
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Huang, P.-Y., Guo, S.-S., Zhang, Y., Lu, J.-B., Chen, Q.-Y., Tang, L.-Q., Zhang, L., Liu, L.-T., Zhang, L., & Mai, H.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.7421 · Cited by 96
Sorensen, S. F., Zhou, W., Dolled-Filhart, M. P., Georgsen, J. B., Wang, Z., Emancipator, K., Wu, D., Busch-Sørensen, M., Meldgaard, P., & Hager, H. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.003 · Cited by 88
PD‐L1 and PD‐L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis
Liang, S. C., Greenwald, R. J., Latchman, Y. E., Rosas, L. E., Satoskar, A. R., Freeman, G. J., & Sharpe, A. H. (2005) · European Journal of Immunology · doi:10.1002/eji.200535458 · Cited by 87
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
Ameratunga, M., Asadi, K., Lin, X., Walkiewicz, M., Murone, C., Knight, S., Mitchell, P., Boutros, P. C., & John, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153954 · Cited by 86
Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., et al. (2015) · PubMed · Cited by 82
Chang, D.-K., Peterson, E., Sun, J., Goudie, C., Drapkin, R., Liu, J. F., Matulonis, U. A., Zhu, Q. K., & Marasco, W. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090075 · Cited by 77
ATM, CTLA4, MNDA, andHEM1in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia
Joshi, A. D., Hegde, G. V., Dickinson, J. D., Mittal, A. K., Lynch, J. C., Eudy, J. D., Armitage, J. O., Bierman, P. J., Bociek, R. G., Devetten, M. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0283 · Cited by 75
Trinath, J., Maddur, M. S., Kaveri, S. V., Balaji, K. N., & Bayry, J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir820 · Cited by 62
Dyck, L., Wilk, M. M., Raverdeau, M., Misiak, A., Boon, L., & Mills, K. H. G. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1906-6 · Cited by 60
Self-citationImmune checkpoint combinations from mouse to man
Ai, M., & Curran, M. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1650-8 · Cited by 47
Gauging the Long-Term Benefits of Ipilimumab in Melanoma
Ribas, A., & Flaherty, K. T. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5041 · Cited by 47
Salem, M. L., & El-Badawy, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i23.2449 · Cited by 43
Fourcade, J. J., Sun, Z., Kudela, P., Janjic, B. M., Kirkwood, J. M., El-Hafnawy, T., & Zarour, H. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903612 · Cited by 40
Dunne, P. D., McArt, D. G., O’Reilly, P. G., Coleman, H. G., Allen, W. L., Loughrey, M. B., Schaeybroeck, S. V., McDade, S. S., Salto‐Tellez, M., Longley, D. B., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0302 · Cited by 39
Tang, Z., Hao, Y.-H., Zhang, E., Xu, C., Zhou, Y., Zheng, X., & Yang, D. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5396 · Cited by 39
Akéus, P., Langenes, V., Kristensen, J., von Mentzer, A., Sparwasser, T. D., Raghavan, S., & Quiding‐Järbrink, M. (2015) · European Journal of Immunology · doi:10.1002/eji.201445058 · Cited by 37
Galvin, K. C., Dyck, L., Marshall, N. A., Stefanska, A. M., Walsh, K. P., Moran, B., Higgins, S. C., Dungan, L. S., & Mills, K. H. G. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1432-8 · Cited by 37
Self-citationTjin, E. P. M., Krebbers, G., Meijlink, K. J., van de Kasteele, W., Rosenberg, E. H., Sanders, J., Nederlof, P. M., van de Wiel, B. A., Haanen, J. B. A. G., Melief, C. J. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0097 · Cited by 35
Shen, L., Shi, H., Gao, Y., Ou, Q., Liu, Q., Liu, Y., Wu, J., Zhang, W., Fan, L., & Shao, L. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.10.001 · Cited by 35
Gill, A. L., Green, S. A., Abdullah, S. A. A., Saout, C. L., Pittaluga, S., Chen, H., Turnier, R., Lifson, J. D., Godin, S., Qin, J., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001217 · Cited by 32
TLR2 Directing PD-L2 Expression Inhibit T Cells Response in Schistosoma japonicum Infection
Gao, Y., Chen, L., Hou, M., Chen, Y., Ji, M., Wu, H.-W., & Wu, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082480 · Cited by 27
PD ‐1 modulates steady‐state and infection‐induced IL ‐10 production in vivo
McBerry, C., Dias, A., Shryock, N., Lampe, K., Gutierrez, F. R. S., Boon, L., Herbert, D. R., & Aliberti, J. (2013) · European Journal of Immunology · doi:10.1002/eji.201343658 · Cited by 22
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Shreders, A. J., Joseph, R. W., Peng, C., Ye, F., Zhao, S., Puzanov, I. J., Sosman, J. A., & Johnson, D. B. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0281 · Cited by 21
Lysaght, J., Jarnicki, A., & Mills, K. H. G. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0288-1 · Cited by 10
Self-citation
Cited by
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Ma, X., Bi, E., Lu, Y., Su, P., Huang, C., Liu, L., Wang, Q., Yang, M., Kalady, M. F., Qian, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.002 · Cited by 1,033
Advances in the understanding and treatment of sepsis-induced immunosuppression
Venet, F., & Monneret, G. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.165 · Cited by 981
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Alsahafi, E., Begg, K., Amelio, I., Raulf, N., Lucarelli, P., Sauter, T., & Tavassoli, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1769-9 · Cited by 525
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Metadata
- Authors
- Dyck, L., & Mills, K. H. G.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2017-04-24
- Volume
- 47
- Issue
- 5
- Pages
- 765-779
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2605157312
- Cited by
- 541
- References
- 167
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.